Triasima Portfolio Management inc. raised its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 838.2% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 34,666 shares of the biopharmaceutical company's stock after buying an additional 30,971 shares during the period. Triasima Portfolio Management inc.'s holdings in Gilead Sciences were worth $3,843,000 as of its most recent SEC filing.
Other hedge funds have also added to or reduced their stakes in the company. Smallwood Wealth Investment Management LLC purchased a new stake in Gilead Sciences during the 1st quarter valued at $25,000. Activest Wealth Management raised its stake in Gilead Sciences by 2,837.5% during the 1st quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company's stock valued at $26,000 after buying an additional 227 shares during the last quarter. Goodman Advisory Group LLC purchased a new stake in Gilead Sciences during the 1st quarter valued at $29,000. Colonial Trust Advisors raised its stake in Gilead Sciences by 304.3% during the 1st quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company's stock valued at $32,000 after buying an additional 213 shares during the last quarter. Finally, Core Alternative Capital grew its position in shares of Gilead Sciences by 370.8% during the 1st quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company's stock valued at $34,000 after acquiring an additional 241 shares during the period. 83.67% of the stock is currently owned by hedge funds and other institutional investors.
Insider Activity at Gilead Sciences
In other Gilead Sciences news, Director Jeffrey Bluestone sold 5,000 shares of the stock in a transaction dated Monday, July 14th. The shares were sold at an average price of $109.74, for a total transaction of $548,700.00. Following the completion of the transaction, the director owned 8,920 shares of the company's stock, valued at $978,880.80. This represents a 35.92% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Johanna Mercier sold 28,000 shares of the stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $118.53, for a total transaction of $3,318,840.00. Following the transaction, the insider directly owned 114,168 shares of the company's stock, valued at $13,532,333.04. This trade represents a 19.70% decrease in their position. The disclosure for this sale can be found here. Insiders sold 82,000 shares of company stock worth $9,402,130 over the last 90 days. Company insiders own 0.27% of the company's stock.
Analyst Ratings Changes
A number of equities research analysts have recently issued reports on the stock. Rothschild & Co Redburn boosted their price objective on shares of Gilead Sciences from $136.00 to $143.00 and gave the company a "buy" rating in a research report on Friday, September 12th. UBS Group boosted their price objective on shares of Gilead Sciences from $108.00 to $112.00 and gave the company a "neutral" rating in a research report on Friday, August 8th. Weiss Ratings reissued a "buy (b)" rating on shares of Gilead Sciences in a research report on Saturday, September 27th. Needham & Company LLC raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price objective for the company in a research report on Friday, July 25th. Finally, Truist Financial raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and boosted their price objective for the company from $108.00 to $127.00 in a research report on Friday, August 8th. Three research analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat.com, Gilead Sciences presently has an average rating of "Moderate Buy" and an average target price of $117.17.
View Our Latest Stock Report on Gilead Sciences
Gilead Sciences Trading Up 2.8%
Shares of GILD stock opened at $116.78 on Wednesday. Gilead Sciences, Inc. has a 52-week low of $84.17 and a 52-week high of $121.83. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32. The firm has a market capitalization of $144.90 billion, a PE ratio of 23.26, a PEG ratio of 0.77 and a beta of 0.34. The stock has a fifty day simple moving average of $114.41 and a two-hundred day simple moving average of $110.06.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The business had revenue of $7.08 billion during the quarter, compared to analyst estimates of $6.95 billion. During the same quarter in the prior year, the business posted $2.01 EPS. Gilead Sciences's revenue for the quarter was up 1.4% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.
Gilead Sciences Dividend Announcement
The business also recently disclosed a quarterly dividend, which was paid on Monday, September 29th. Shareholders of record on Monday, September 15th were issued a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a dividend yield of 2.7%. The ex-dividend date of this dividend was Monday, September 15th. Gilead Sciences's dividend payout ratio is 62.95%.
Gilead Sciences Profile
(
Free Report)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
